Joint Formulary & PAD

Harvoni - Hepatitis C

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Harvoni
Indication :
Hepatitis C
Group Name :
Keywords :
Hep C, NICE, cirrhosis, child-pugh class A, HCV, hepatitis c virus, chronic, genotype
Brand Names Include :
Ledipasvir 90mg/sofosbuvir 400mg
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

Implementation of NICE TA 363 - Ledipasvir-sofosbuvir is recommended by NICE guidance. Funding responsibility rests with NHS England, treatment should remain with the specialist in secondary care.